Presentation TCT 2024 TCT 668: Use of Antiplatelet Agents in Patients With Myocardial Bridge: Insights From the RIALTO Registry Presenter: Domenico D'Amario October 27, 2024
Presentation TCT 2023 Antiplatelet Agents for Patients Undergoing PCI: Options and Pharmacologic Considerations Presenter: Harold Dauerman October 24, 2023
Presentation TCT 2019 The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease Presenter: Marc Bonaca September 26, 2019
Presentation SIF 2019 Fundamentals of Pharmacology: What You Need to Know as an Interventionalist Presenter: Sripal Bangalore March 27, 2019
Presentation TCT 2017 Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update Presenter: Debabrata Mukherjee, E. Murat Tuzcu, Dimitrios Alexopoulos November 01, 2017
Presentation TCT 2016 Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco October 31, 2016
Presentation TCT 2016 TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES Presenter: Dimitrios Alexopoulos, Laurent Bonello, Bjorn Redfors October 31, 2016
Presentation TCT 2016 TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events Presenter: Dimitrios Alexopoulos, Laurent Bonello, Christine Chung October 31, 2016
Presentation TCT 2016 TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber October 31, 2016
Presentation TCT 2016 TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi October 31, 2016
Presentation TCT 2016 Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First! Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt October 30, 2016
Presentation TCT 2016 Reversal of Chronic Anticoagulation: When, What, and How Effective? Presenter: Paul A. Gurbel, James A. Reiffel October 30, 2016
Presentation TCT 2016 Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents Presenter: Paul A. Gurbel, Christopher B. Granger October 30, 2016
Presentation TCT 2016 Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents Presenter: David J. Moliterno October 30, 2016
Presentation TCT 2016 Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents Presenter: Paul A. Gurbel, Harvey D. White October 30, 2016
Presentation TCT 2015 Is There a Role for Oral Anticoagulants After PCI? Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson October 15, 2015
Presentation TCT 2015 Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda October 15, 2015
Presentation TCT 2015 Should You Bridge in Stented Patients Needing Surgery? Presenter: Eric R. Bates, Neal S. Kleiman, David F. Kong October 15, 2015
Presentation Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in STEMI Patients Presenter: Guido Parodi January 20, 2015
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014